Advancing Next Generation Precision Therapeutics
Azkarra Therapeutics targets pathways at the intersection of DNA Damage Repair and Immune Response
Azkarra is a precision therapeutics company
The discovery of the synthetic lethal interaction between PARP inhibition and BRCA mutation by Ashworth and others has fueled considerable effort in targeting other DNA Damage Response (DDR) pathways. There is increasing evidence that the DDR influences not only cancers, but also affects immunity and inflammation. Founded by Alan Ashworth, PhD, FRS, Azkarra Therapeutics aims to exploit molecular targets at the intersection of DDR and immune response and develop novel therapeutics for cancer and inflammatory diseases.
Azkarra focuses on discovering and developing small molecule modulators of DNA damage response (DDR) pathways that promises to have therapeutic benefit in oncology and inflammatory disease settings
Azkarra is developing novel therapies targeting pathway molecules associated with DNA damage repair, across the multitude of DDR pathways that afford new opportunities to treat cancer and inflammatory diseases.
Azkarra is developing a novel next generation multi-PARPi with high affinity against PARP1, PARP2, PARP5a, PARP5b and PARP7. This unique multi-PARP inhibition profile promotes pro-apoptotic pathways and restores anti-tumor immunogenicity providing potential for broader anti-tumor activity in DDR dependent tumors, including PARP1/2i resistance settings.
PARG inhibition exploits and exacerbates replication deficiencies of cancer cells and is a new MOA for treatment of HRD cancers. PARG inhibitors complement PARP inhibitors in targeting a broad range of cancer types with different sources of genomic instability including settings of PARP1/2i resistance.
OGG1 inhibition leads to accumulation of DNA damage, cell cycle arrest and ultimately apoptosis in cancer cells with high oxidative stress. OGG1i also reduces pro-inflammatory cytokine signaling and shows therapeutic benefit in preclinical models of inflammation and fibrosis.
Our Development Pipeline
.png)
